| Literature DB >> 22522397 |
Bendong Chen1, Mingliang Ning, Guangshun Yang.
Abstract
The study investigated the immunity and antioxidant potential of paeonol by employing a hepatocellular carcinoma (HCC) rat model. Three doses of paeonol (20, 40, 60 mg/kg b.w. orally) were administrated to diethylnitrosamine (DEN)-induced HCC rats. Results showed that paeonol significantly reduced the serum AST, ALT, ALP, GGT, AFU and liver MDA levels, increased serum WBC, TP, ALB, A/G, TNF-α and IFN-γ and liver antioxidant enzymes activities (SOD, CAT, GSH-Px, GR) in HCC rats. Altogether, these results suggest that the paeonol could effectively decrease oxidative injury and improve immunity function in HCC rats.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22522397 PMCID: PMC6268820 DOI: 10.3390/molecules17044672
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Inhibitory effects of tumour growth by paeonol.
| Group | Number (n) | Death (n) | Survival rate (%) |
|---|---|---|---|
| I | 10 | 0 | 100 |
| II | 10 | 2 | 80 |
| III | 10 | 1 | 90 |
| IV | 10 | 0 | 100 |
| V | 10 | 0 | 100 |
| VI | 10 | 0 | 100 |
Values are given as mean ± SD from six rats in each group; group I = Normal group; group II = DEN control group; group III = DEN+ paeonol (20 mg/kg); group IV = DEN+ paeonol (40 mg/kg); group V = DEN+ paeonol (60 mg/kg); group VI = DEN+ Fufang Banmao capsule (15 mg/kg b.w.).
Effects of paeonol on serum AST, ALP, ALT, GGT and AFU in HCC rats.
| Group | AST (U/L) | ALP (U/L) | ALT (U/L) | GGT (U/L) | AFU (U/L) |
|---|---|---|---|---|---|
| I | 288.82 ± 18.19 | 141.61 ± 9.62 | 63.55 ± 3.04 | 17.57 ± 1.75 | 30.14 ± 2.77 |
| II | 392.16 ± 20.66 b | 201.17 ± 12.43 b | 91.14 ± 4.01 b | 121.63 ± 8.63 b | 174.11 ± 9.05 b |
| III | 351.32 ± 19.18 d | 180.12 ± 8.92 d | 79.14 ± 3.01 d | 97.45 ± 5.11 d | 152.09 ± 9.29 d |
| IV | 331.24 ± 24.16 d | 156.22 ± 6.84 d | 70.31 ± 2.81 d | 66.43 ± 3.96 d | 111.27 ± 7.08 d |
| V | 297.63 ± 15.11 d | 126.18 ± 7.84 d | 64.92 ± 2.99 d | 48.12 ± 2.74 d | 81.36 ± 6.83 d |
| VI | 289.68 ± 19.51 d | 132.35 ± 9.59 d | 60.26 ± 3.85 d | 33.71 ± 2.94 d | 65.62 ± 5.47 d |
b p < 0.01, compared with group I; c p < 0.05; d p < 0.01, compared with group II; group I = Normal group; group II = DEN control group; group III = DEN+ paeonol (20 mg/kg); group IV = DEN+ paeonol (40 mg/kg); group V = DEN+ paeonol (60 mg/kg); group VI = DEN+ Fufang Banmao capsule (15 mg/kg b.w.).
Effect of paeonol on serum WBC, TP, ALB and A/G.
| Group | WBC (×109/L) | TP (g/L) | ALB (g/L) | A/G |
|---|---|---|---|---|
| I | 30.11 ± 1.83 | 66.39 ± 1.92 | 38.29 ± 1.72 | 1.71 ± 0.09 |
| II | 22.17 ± 1.08 b | 59.18 ± 1.68 b | 34.15 ± 1.81 b | 1.53 ± 0.11 b |
| III | 25.81 ± 1.22 c | 62.71 ± 1.99 c | 35.05 ± 1.83 | 1.55 ± 0.09 |
| IV | 27.84 ± 1.65 c | 63.92 ± 2.02 c | 35.81 ± 1.29 | 1.64 ± 0.06 d |
| V | 29.62 ± 1.09 d | 67.16 ± 2.15 d | 37.21 ± 1.47 c | 1.69 ± 0.96 d |
| VI | 27.37 ± 1.11 d | 70.13 ± 2.74 d | 39.84 ± 1.61 c | 1.85 ± 0.88 d |
b p < 0.01, compared with group I; c p < 0.05; d p < 0.01, compared with group II; group I = Normal group; group II = DEN control group; group III = DEN+ paeonol (20 mg/kg); group IV = DEN+ paeonol (40 mg/kg); group V = DEN+ paeonol (60 mg/kg); group VI = DEN+ Fufang Banmao capsule (15 mg/kg b.w.).
Effect of paeonol on serum TNF-α and IFN-γ.
| Group | TNF-α (pg/mL) | IFN-γ (pg/mL) |
|---|---|---|
| I | 613.72 ± 28.72 | 619.48 ± 24.91 |
| II | 972.38 ± 52.38 b | 328.32 ± 15.51 b |
| III | 904.22 ± 42.57 a | 420.24 ± 18.94 d |
| IV | 811.37 ± 38.42 d | 512.33 ± 19.66 d |
| V | 677.83 ± 32.64 d | 592.83 ± 25.62 d |
| VI | 614.52 ± 42.52 d | 631.7 ± 39.32 d |
b p< 0.01, compared with group I; d p< 0.01, compared with group II; group I = Normal group; group II = DEN control group; group III = DEN+ paeonol (20 mg/kg); group IV = DEN+ paeonol (40 mg/kg); group V = DEN+ paeonol (60 mg/kg); group VI = DEN+ Fufang Banmao capsule (15 mg/kg b.w.).
Effect of paeonol on spleen CD4+, CD8+ and CD4+/CD8+.
| Group | CD4+ (%) | CD8+ (%) | CD4+/CD8+ |
|---|---|---|---|
| I | 48.08 ± 4.19 | 25.86 ± 1.76 | 1.85 ± 0.24 |
| II | 31.47 ± 2.76 b | 33.16 ± 1.95 b | 0.94 ± 0.39 a |
| III | 39.52 ± 2.72 c | 24.76 ± 1.38 d | 1.59 ± 0.22 c |
| IV | 40.13 ± 3.82 c | 25.15 ± 1.81 d | 1.59 ± 0.28 c |
| V | 39.21 ± 4.52 c | 24.17 ± 2.83 d | 1.62 ± 0.23 c |
| VI | 37.58 ± 4.81 c | 22.13 ± 2.21 d | 1.68 ± 0.34 c |
a p < 0.01; b p < 0.01, compared with group I; c p < 0.01; d p < 0.01, compared with group II; group I = Normal group; group II = DEN control group; group III = DEN+ paeonol (20 mg/kg); group IV = DEN+ paeonol (40 mg/kg); group V = DEN+ paeonol (60 mg/kg); group VI = DEN+ Fufang Banmao capsule (15 mg/kg b.w.).
Effect of paeonol on liver MDA, GSH, SOD, CAT, GSH-Px and GR activities.
| Group | MDA(nmol/mg prot) | GSH (nmol/mg) | SOD (U/mg prot) | CAT (U/mg prot) | GSH-Px (U/mg prot) | GR (U/mg prot) |
|---|---|---|---|---|---|---|
| I | 3.53 ± 0.16 | 74.39 ± 3.61 | 321.32 ± 15.05 | 63.28 ± 2.11 | 51.81 ± 1.77 | 37.24 ± 1.42 |
| II | 7.84 ± 0.39 b | 39.19 ± 1.74 b | 161.19 ± 11.39 b | 32.14 ± 1.72 b | 26.02 ± 1.41 b | 16.93 ± 1.39 b |
| III | 5.98 ± 0.22 d | 52.77 ± 1.91 d | 199.48 ± 11.52 d | 44.17 ± 1.93 d | 35.63 ± 1.62 d | 27.18 ± 1.66 d |
| IV | 4.77 ± 0.17 d | 67.14 ± 2.82 d | 267.14 ± 11.62 d | 58.11 ± 2.72 d | 45.28 ± 1.83 d | 34.14 ± 1.95 d |
| V | 3.68 ± 0.21 d | 75.03 ± 2.92 d | 316.13 ± 14.71 d | 62.63 ± 2.99 d | 52.33 ± 2.41 d | 38.05 ± 1.51 d |
| VI | 5.05 ± 0.29 d | 69.41 ± 2.77 d | 287.48 ± 19.66 d | 58.47 ± 2.81 d | 48.51 ± 2.73 d | 35.62 ± 1.88 d |
b p < 0.01, compared with group I; d p < 0.01, compared with group II; group I = Normal group; group II = DEN control group; group III = DEN+ paeonol (20 mg/kg); group IV = DEN+ paeonol (40 mg/kg); group V = DEN+ paeonol (60 mg/kg); group VI = DEN+ Fufang Banmao capsule (15 mg/kg b.w.).